Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid:: Epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection

被引:230
作者
Wobus, CE
Hügle-Dörr, B
Girod, A
Petersen, G
Hallek, M
Kleinschmidt, JA
机构
[1] Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany
[2] Univ Heidelberg, Inst Genet Mol, Heidelberg, Germany
[3] Genzentrum Munchen, Munich, Germany
关键词
D O I
10.1128/JVI.74.19.9281-9293.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The previously characterized monoclonal antibodies (MAbs) Al, A69, B1, and A20 are directed against assembled or nonassembled adeno-associated virus type 2 (AAV-2) capsid proteins (A. Wistuba, A. Kern, S. Weger, D, Grimm, and J. A. Kleinschmidt, J, Virol. 71:1341-1352, 1997). Here we describe the linear epitopes of A1, A69, and B1 which reside in VP1, VP2, and VP3, respectively, using gene fragment phage display library, peptide scan, and peptide competition experiments. In addition, MAbs A20, C24-B, C37-B, and D3 directed against conformational epitopes on AAV-2 capsids were characterized. Epitope sequences on the capsid surface were identified by enzyme-linked immunoabsorbent assay using AAV-2 mutants and AAV serotypes, peptide scan, and peptide competition experiments. A20 neutralizes infection following receptor attachment by binding an epitope formed during AAV-2 capsid assembly. The newly isolated antibodies C24-B and C37-B inhibit AAV-2 binding to cells, probably by recognizing a loop region involved in binding of AAV-2 to the cellular receptor. In contrast, binding of D3 to a loop near the predicted threefold spike does not neutralize AAV-2 infection. The identified antigenic regions on the AAV-2 capsid surface are discussed with respect to their possible roles in different steps of the viral life cycle.
引用
收藏
页码:9281 / 9293
页数:13
相关论文
共 55 条
  • [1] CRYO-ELECTRON MICROSCOPY OF VIRUSES
    ADRIAN, M
    DUBOCHET, J
    LEPAULT, J
    MCDOWALL, AW
    [J]. NATURE, 1984, 308 (5954) : 32 - 36
  • [2] [Anonymous], 1989, MOL ASPECTS PICORNAV
  • [3] [Anonymous], 1988, Antibodies: A Laboratory Manual
  • [4] Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses
    Bantel-Schaal, U
    Delius, H
    Schmidt, R
    zur Hausen, H
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (02) : 939 - 947
  • [5] Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab′γ)2 antibody
    Bartlett, JS
    Kleinschmidt, J
    Boucher, RC
    Samulski, RJ
    [J]. NATURE BIOTECHNOLOGY, 1999, 17 (02) : 181 - 186
  • [6] Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
    Bartlett, JS
    Wilcher, R
    Samulski, RJ
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (06) : 2777 - 2785
  • [7] PARVOVIRUS REPLICATION
    BERNS, KI
    [J]. MICROBIOLOGICAL REVIEWS, 1990, 54 (03) : 316 - 329
  • [8] BLACKLOW NR, 1968, J NATL CANCER I, V40, P319
  • [9] STRUCTURE, SEQUENCE, AND FUNCTION CORRELATIONS AMONG PARVOVIRUSES
    CHAPMAN, MS
    ROSSMANN, MG
    [J]. VIROLOGY, 1993, 194 (02) : 491 - 508
  • [10] Immune responses to adenovirus and adeno-associated virus in humans
    Chirmule, N
    Propert, KJ
    Magosin, SA
    Qian, Y
    Qian, R
    Wilson, JM
    [J]. GENE THERAPY, 1999, 6 (09) : 1574 - 1583